Covalon Technologies Ltd. (USD) Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, Europe, the Middle East, Asia, Latin America, and internationally. The company has 3 proprietary platform technologies, including collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform that is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity; and medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. Its products include wound care dressings; surgical and peri-operative products; and infection management products. The company offers its products under the Covalon brand name through third-party distribution networks and company's direct sales force. It serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. The company is headquartered in Mississauga, Canada.

Covalon Technologies Ltd. (USD) Active

1660 Tech Avenue, Mississauga, ON, CA, L4W 5S7

Stock Price USD

Price Change

Last Dividend USD

Latest Rating

CVALF's stock peer is APTCF (Advanced Proteome Therapeutics Corporation)

CVALF's stock peer is BIOAF (Bioasis Technologies Inc.)

CVALF's stock peer is BITRF (Biotron Limited)

CVALF's stock peer is CHNXF (ChitogenX Inc.)

CVALF's stock peer is CMVLF (Cellectis S.A.)

CVALF's stock peer is CPMV (Mosaic ImmunoEngineering Inc.)

CVALF's stock peer is CRPOF (Ceapro Inc.)

CVALF's stock peer is DMTTF (Small Pharma Inc.)

CVALF's stock peer is RVXCF (Resverlogix Corp.)

Healthcare Biotechnology

Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, Europe, the Middle East, Asia, Latin America, and internationally. The company has 3 proprietary platform technologies, including collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform that is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity; and medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. Its products include wound care dressings; surgical and peri-operative products; and infection management products. The company offers its products under the Covalon brand name through third-party distribution networks and company's direct sales force. It serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. The company is headquartered in Mississauga, Canada.

20%

Dcf Rating

80%

Return On Equity

100%

Return On Assets

60%

Debt To Equity

40%

Price To Earnings

40%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Recent News

Covalon Reports Fifth Consecutive Quarter of Positive Earnings

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2025 second quarter results for the period ended March 31, 2025, along with a number of important recent achievements and highlights. Brent Ashton, Covalon's Chief Executive Officer, reported, “In the past few months, the Covalon team has delivered on several of our key priorities that have led to expanded s.

2025-05-28 07:00:00

Covalon Announces Exciting New Clinical Research Evaluating VALGuard® Vascular Access Line Guard

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that exciting results from a clinical study evaluating the use of its VALGuard® Vascular Access Line Guard will be presented at two notable scientific meetings in the fall and are advancing through the publication process in a well-regarded academic journal. The study, conducted independent of Covalon, was a prospectiv.

2025-05-27 07:00:00

Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2025 Financial Results

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2025 financial results on Wednesday, May 28, 2025, before markets open. A conference call and webcast to discuss the financial results will be held on Wednesday, May 28, 2025, at 8:30am ET. To view, listen to, and participate in the live webcast, please follow the link below: https://events.q4inc.com/attende.

2025-05-21 07:00:00

Covalon Retains Financial and Strategic Advisor to Advise on Shareholder Value-Enhancing Opportunities

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that it has engaged Origin Merchant Partners as its financial and strategic advisor to advise on a range of opportunities aimed at maximizing shareholder value and expanding the reach of its innovative medical technologies. With the assistance of its financial and strategic advisor, the Company is exploring a range of.

2025-05-20 07:00:00

Covalon Announces Promotion of Kim Crooks to Chief Operating Officer and Appointment to Board of Directors

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is pleased to announce the promotion of Ms. Kim Crooks to the position of Chief Operating Officer (COO), effective immediately. In addition to her new role, Ms. Crooks has been appointed to Covalon's Board of Directors. Ms. Crooks rejoined Covalon in early 2024 as Senior Vice President – Operations, bringing with her a wealth of exper.

2025-05-15 07:00:00

Covalon to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 6, 2025

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that it will be presenting at the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, May 6, 2025 at 2:30 pm ET in Room 104 B at the Metro Toronto Convention Centre in Toronto. Brent Ashton, CEO of Covalon, will be hosting the presentation and answering questions at the conclusion. During.

2025-04-30 07:00:00

Covalon to Present at the Planet MicroCap Showcase: VEGAS on April 23, 2025

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that they will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 4:30 pm (Local Time -PST). Brent Ashton, Covalon's CEO will review why Covalon is in the “sweet spot” in the microcap sector as an undervalued, cash rich, profitable healthcare compa.

2025-04-17 07:00:00

Covalon Technologies Ltd. Poised for Strong Benefit From Positive US Tariff Outcome

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company is pleased to announce the very positive outcome for the Company with regards to the April 2, 2025 tariff announcements by U.S. President Donald Trump. Under provisions outlined in the United States-Mexico-Canada Agreement (USMCA), certain products that meet the agreement's rules of origin requirements are not subject to the recent tar.

2025-04-03 09:06:00

Covalon Announces Voting Results from Fiscal 2024 Annual Meeting of Shareholders

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the results of the matters voted upon at its Fiscal 2024 Annual Meeting of Shareholders (“AGM”) held March 19, 2025. Shareholders voted in favour of all items of business and each item of business was approved by the requisite number of votes. The matters included the election of the Board of Directors and the appointm.

2025-03-20 07:00:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions